Here are the DEF 14A proxy statements from Becton, Dickinson and Co. (BDX) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow BDX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDX filings page.
Becton, Dickinson and Company is asking shareholders to vote at its virtual 2026 annual meeting on four items: electing 13 directors, ratifying Ernst & Young as independent auditor, approving named executive officer pay on an advisory basis, and increasing the shares available under its 2004 equity-based compensation plan by 3,935,000 shares.
The materials highlight record fiscal 2025 revenue of $21.8 billion, GAAP EPS of $5.82 and record adjusted diluted EPS of $14.40, supported by margin expansion from its BD Excellence program. BD returned $2.2 billion to shareholders through buybacks and dividends and marked its 54th consecutive annual dividend increase.
BD also describes the planned Reverse Morris Trust transaction combining its Biosciences and Diagnostic Solutions businesses with Waters Corporation, which is expected to generate about $4 billion in cash for BD and give its shareholders roughly 39% ownership of the new life sciences company, alongside extensive detail on governance, sustainability goals and risk oversight.